Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

Top US Stock Gainers and Losers for Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

Performance

52-Week Range 66.7% below 52-week high

159.89

156.0052W Low 479.7952W High

1 Week 31.3% below 1-week high

156.001W Low 232.881W High

Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY) traded between $156.00 and $479.79 over the past 52 weeks and last traded at $159.89, 66.7% below its 52-week high. Over the past week it ranged between $156.00 and $232.88.

Past 12 Months

-29.5%

-27.3%

-27.4%

-46.3%

-60.0%

-63.2%

1W -$66.90

1M -$60.00

3M -$60.44

6M -$138.04

YTD -$240.28

1Y -$274.18

ALNY was -63.2% over the past year, -46.3% over six months, -60.0% year to date, -29.5% in the last week.

12 Months vs Market

ALNY

-63.2%

DIA

+9.2%

SPY

+10.4%

QQQ

+8.4%

IWM

+14.0%

Over the past 12 months ALNY returned -63.2% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 2.00× 3-mo avg

Today 3,759,971 3-mo avg 1.9M

5.4M

2.3M

1.9M

1.7M

YTD

1.5M

ALNY most recently traded 3,759,971 shares against a 3-month average daily volume of 1.9M.

More News

Alnylam (ALNY) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum ↗

October 16, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth ↗

October 08, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Alnylam Pharmaceuticals Q3 Earnings Call Highlights ↗

October 29, 2026

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Premarket Gainers and Losers on Oct. 29, 2026 ↗

October 29, 2026

Via Chartmill

October 29, 2026

From Alnylam Pharmaceuticals

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial ↗

October 26, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

October 23, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

October 15, 2026

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

September 29, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial ↗

September 19, 2026

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Via Benzinga

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Via Benzinga

Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP

August 24, 2026

Via NewMediaWire

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026